Tu canal independiente de oncología en español
Top resúmenes y presentaciones
ESMO 2024
GINECOLÓGICO
Regístrate aquí para recibir más contenidos
Registrarse
CERVICAL
Long-term patient-reported outcomes (PROs) with
atezolizumab (atezo) + bevacizumab (bev) and
chemotherapy (CT) for metastatic, persistent or recurrent
cervical cancer (R/M CC): BEATcc (ENGOT-Cx10/GEICO
68-C/JGOG1084/GOG-3030) randomised phase 3 trial
722P
A phase II study of cadonilimab plus chemotherapy in
persistent recurrent/ metastatic cervical cancer patients
who failed previous immuno/chemotherapy
723P
Chemotherapy plus tislelizumab in young patients with
cervical cancer preserve fertility: a phase II study
728P
Efficacy and Safety of Pembrolizumab plus Olaparib
Combination Therapy in Recurrent Cervical Cancer
Progressed on Platinum-Based Chemotherapy: Results
from the phase II trial of GOTIC-025
726P
Preliminary Outcomes from a Phase 1b/2 Study of the Highly
Potent PI3K-mTOR Dual Inhibitor WX390 Combined with
Toripalimab in Patients with Advanced Cervical Cancer
724P
Treatment of patients with metastatic or relapsed cervical
cancer: results from a quality assurance program of the
AGO Study Group
725P